Itaconix H1 revenues surge 73% as it moves closer to profitability
Itaconix (ITX) , a producer of sustainable plant-based polymers, announced its interim results for the half year ended June 30, 2025 (H1 2025).
Itaconix reported record H1 2025 revenues of US$4.8m, up 30% half-on-half from $3.7m in H2 2024, and up 73% year-on-year from US$2.8m in H1 2024. Likewise, gross profit jumped to US$1.7m, up 55% year-on-year, while overall gross profit margin was 35%, up 4pts from H2 2024. Within ITX's core Performance Ingredients business, gross profit margin was up 5pts to 45%, while the SPARX Formulated Solutions division saw profit margins rise 3pts to 13%.
The company made substantial progress toward profitability in H1 2025, with adjusted EBITDA improving to $(0.2)m, compared to $(0.8)m in H2 2024 and $(1.0)m in H1 2024. Loss after tax also improved to $(0.4)m, compared to $(0.9)m in H2 2024 and $(1.0)m in H1 2024.
In terms of balance sheet, ITX ended the period with a comfortable cash balance of US$5.7m - a moderate reduction from the US$6.7m reported at year-end FY24, reflecting significant investments in raw material and finished goods inventories to support customer growth and mitigate supply chain risk.
John R. Shaw, CEO, on current trading and outlook: "Looking ahead, we remain confident in delivering on the Board's full-year expectations for 2025 and in our mid-term path to profitability. With cash resources of $5.7 million at 30 June 2025 and a growing pipeline of opportunities, we are well positioned to continue our progress."
View from Vox
A highly positive interim update from Itaconix as it reports record revenues and gross profits, growing margins, and a solid balance sheet to support future expansion. Momentum in its core Performance Ingredients business remains strong, while the recent launch of BIO Asterix adds a third revenue stream, and uptake in the SPARX program continues to build. With these drivers in place, the company is scaling rapidly toward profitability, reaffirming its full-year forecast.
The strong results mark an inflection point for ITX, reflecting its evolution beyond its core business of scale inhibitors and odour neutralisers into a diverse stream of recurring revenues that underpin long-term profitable growth. The launch of the BIO Asterix specialty monomers represents another milestone in this evolution.
Turnover was US$4.8m in H1 2025, a 73% jump year-on-year, reflecting both increased market share in cleaning applications and the early contribution from the new initiatives, including the SPARX program. Gross profit margin was over 35%, demonstrating the strength of the repositioned revenue base and value of the company's ingredients. Loss after tax halved from H2 2024 to $(0.4)m, and is on a clear trajectory to breakeven in the medium term.
Looking ahead, ITX entered the second half with strong sales momentum and on track to meet full-year expectations. Tariffs have not had a significant impact, being mitigated by ITX's selective price adjustments and supply chain shifts, and favourable currency movements. With a robust cash balance of US$5.7m on June 30, 2025 and a steadily growing pipeline, ITX is well-positioned for further growth.
Follow News & Updates from Itaconix:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
